Cargando…
Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study
SIMPLE SUMMARY: The management of cardiovascular adverse events in patients with relapsed/refractory multiple myeloma undergoing treatment with carfilzomib can be challenging. Herein, we evaluated the potential cardioprotective effect of daratumumab when administered in combination with carfilzomib...
Autores principales: | Terpos, Evangelos, Stamatelopoulos, Kimon, Makris, Nikolaos, Georgiopoulos, Georgios, Ntanasis-Stathopoulos, Ioannis, Gavriatopoulou, Maria, Laina, Ageliki, Eleutherakis-Papaiakovou, Evangelos, Fotiou, Despina, Kanellias, Nikolaos, Malandrakis, Panagiotis, Delialis, Dimitris, Andreadou, Ioanna, Kastritis, Efstathios, Dimopoulos, Meletios A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533991/ https://www.ncbi.nlm.nih.gov/pubmed/34680206 http://dx.doi.org/10.3390/cancers13205057 |
Ejemplares similares
-
Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome
por: Gavriatopoulou, Maria, et al.
Publicado: (2020) -
Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma
por: Gavriatopoulou, Maria, et al.
Publicado: (2020) -
Prevalence of MGCS Among Patients With Monoclonal Gammopathies
por: Theodorakakou, Foteini, et al.
Publicado: (2023) -
Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study
por: Terpos, Evangelos, et al.
Publicado: (2021) -
PB2124: EFFICACY AND IMMUNE MODULATION OF DARATUMUMAB PLUS IMID COMBINATION IN PATIENTS REFRACTORY TO BOTH AGENTS“
por: Kostopoulos, Ioannis, et al.
Publicado: (2023)